News

Sysmex and Shionogi co-developed the HISCL TARC Assay Kit and the HISCL ANP Assay Kit in 2014 and have been promoting business expansion in the Japanese market for a long time, with Shionogi as the legal manufacturer and Sysmex as the seller.

Sysmex has responded flexibly to diversified medical needs in cooperation with Shionogi to reduce the burden on patients and improve the quality of testing, such as obtaining insurance coverage for the unique item HISCL TARC Assay Kit in April 2014 as an aid to determine the severity of atopic dermatitis, followed by additional indications as an aid for assessment of COVID-19 aggravation risk in June 2021 and an aid to diagnose drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS) in July 2023.

As part of its long-term corporate strategy, Sysmex strives to expand its business domain by strengthening existing businesses and creating new ones. In the existing field of immunochemistry, Sysmex is promoting early expansion of reagent parameters and global market penetration. In order to successfully accommodate the rapidly changing market environment, it is essential to make timely business decisions, ensure stable supplies, and establish an effective service and support system. To strengthen these structures, Sysmex and Shionogi have reached an agreement for the transfer of manufacturing and marketing approval to Sysmex and to proceed with the transfer of reagent manufacturing. Going forward, Sysmex-manufactured reagents will be gradually introduced into the market.